US Pharma MarketingCurrent heads of CBER, CDER snag permanent jobs
FDA makes Michael Davis and Karim Mikhail permanent CDER and CBER directors, and names Jared Seehafer its first deputy commissioner for AI. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
The FDA has made permanent the leaders of CDER and CBER, stabilizing key agency posts as a new commissioner awaits confirmation.
The decision was announced by HHS on Tuesday afternoon, naming ...
Source: Endpoints News